within Pharmacolibrary.Drugs.ATC.L;

model L01AA07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 3.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0025,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Trofosfamide is an oxazaphosphorine alkylating agent used primarily in the treatment of various malignancies, including non-Hodgkin lymphoma, soft tissue sarcomas, and some pediatric cancers. It is a prodrug structurally related to cyclophosphamide and ifosfamide, undergoing hepatic metabolism to form active cytotoxic metabolites. Trofosfamide has been used in both adult and pediatric oncology, often administered orally. It is not approved by the U.S. FDA and is mainly available in certain European countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult patients based on values reported for structurally related oxazaphosphorines (cyclophosphamide and ifosfamide), as no direct clinical PK studies for trofosfamide have been published.</p><h4>References</h4><ol><li><p>Wagner, A, et al., &amp; Boos, J (1997). Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. <i>Anti-cancer drugs</i> 8(5) 419–431. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9215603/&quot;>https://pubmed.ncbi.nlm.nih.gov/9215603</a></p></li><li><p>Preiss, R, et al., &amp; Niederwieser, D (2004). Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans. <i>Cancer chemotherapy and pharmacology</i> 53(6) 496–502. DOI:<a href=&quot;https://doi.org/10.1007/s00280-003-0757-y&quot;>10.1007/s00280-003-0757-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15138712/&quot;>https://pubmed.ncbi.nlm.nih.gov/15138712</a></p></li><li><p>Hempel, G, et al., &amp; Boos, J (1997). Pharmacokinetics of trofosfamide and its dechloroethylated metabolites. <i>Cancer chemotherapy and pharmacology</i> 40(1) 45–50. DOI:<a href=&quot;https://doi.org/10.1007/s002800050623&quot;>10.1007/s002800050623</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9137528/&quot;>https://pubmed.ncbi.nlm.nih.gov/9137528</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01AA07;
